BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Higher risk of mortality in previously hospitalized patients

Higher Risk of Mortality in Previously Hospitalized Patients: Insights From ATTRibute-CM


Ahmad Masri1, Michele Emdin2, Keyur Shah3, Kunal Bhatt4,...

Related Keywords

Australia ,Portland ,Oregon ,United States ,Dallas ,Texas ,Brisbane ,Queensland ,San Francisco ,California ,Palo Alto ,Perth ,Western Australia ,Stanford University ,Italy ,Dariusz Korczyk ,Kunal Bhatt ,Michel Khouri ,Kevin Alexander ,Jonathanc Fox ,Noel Dasgupta ,Ahmad Masri ,Michele Emdin ,Martha Grogan ,Michael Johnstone ,Suresh Siddhanti ,Olakunle Akinboboye ,Fondazioneg Monasterio ,Mazen Hanna ,Leonid Katz ,Keyur Shah , ,Astrazeneca ,University Of Pittsburgh Medical Center ,Syneos Health Medical Communications ,Steward Health Care ,Pfizer ,Bridgebio Pharma Inc ,Janssen Pharmaceuticals ,Virginia Commonwealth University Health ,Stanford University School Of Medicine ,Shweta Bio Pharma Inc ,Indiana University School Of Medicine ,Duke Health ,Bio Pharma Inc ,Novo Nordisk ,York Heart Association ,Oregon Health Science University ,Higher Risk ,Previously Hospitalized Patients ,Insights From ,Kaitlyn Lam ,Prem Soman ,Science University ,Commonwealth University Health ,Health Care ,University School ,Barbara Zucker School ,Alexandra Hospital ,Australia Advanced Heart Failure ,Cardiac Transplant Service ,Pittsburgh Medical Center ,Bio Pharma ,Baseline Characteristics ,Meier Curve ,Cumulative Events ,Bridgebio Pharma ,New York Heart Association ,Shweta Rane ,